Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Bronchiectasis Therapeutic Market size was valued at USD 532.08 million in 2024 and is expected to reach USD 1.17 billion by 2037, registering around 6.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of bronchiectasis therapeutic is evaluated at USD 560.57 million.
The global market for therapies for bronchiectasis is anticipated to increase at a faster rate due to the rising prevalence of respiratory illnesses. The primary driver of the market growth is the accessibility of inexpensive medications, or off-label generics, in both developed and developing nations. An additional piece of evidence supporting the significant contribution of chronic respiratory disorders to premature morbidity and death is the fact that reports state that approximately 545 million people worldwide, or 7·4% of the total population, currently live with a chronic respiratory ailment.
One major factor propelling the bronchiectasis therapeutic market is the accessibility of inexpensive off-label generics in both developed and developing countries. The supply of affordable off-label generics in both developed and developing countries is a major factor propelling the market for bronchiectasis treatment's revenue growth. The same active ingredient is found in both branded and generic pharmaceuticals, although generics are more affordable than novel pharmaceuticals.
Bronchiectasis Therapeutic Market: Growth Drivers and Challenges
Growth Drivers
- Growing Awareness About the Disease - Market growth will be supported by an increase in global awareness of the disease. For example, to raise awareness about bronchiectasis, global lung health organizations from the USA, Europe, Australia, and Asia have joined together to declare July 1, 2022, as the first World Bronchiectasis Awareness Day, according to data published by the National Center for Biotechnology Information on July 1, 2022. The objective of the day is to raise awareness and increase knowledge about bronchiectasis worldwide, to effectively diagnose and manage this disease which has not been adequately addressed.
- Expansion of Biologics and Targeted Therapies - In the bronchiectasis drug market, biological products and targeted therapies are gaining attention. Specific molecules or pathways associated with the disease process are selectively targeted by these treatments. The potential for accurate and effective treatment is offered by biologicals like monoclonal antibodies and new small molecules. In patients with bronchiectasis, research continues to explore the use of targeted therapy for reducing inflammation, controlling infections, and improving lung function.
Challenges
- High Development Cost and Regulatory Obstructions - It may be costly and time-consuming to develop and market new bronchiectasis therapeutic. Pharmaceutical companies may find it difficult to access the market, due to a strict trial procedure, regulatory requirements, and difficulties in accessing the markets. Investment in R&D may be deterred by high development costs associated with the conduct of clinical studies and access to Regulatory Authorisations, which can limit innovation.
- Presence of Alternative Treatment Options is Set to hamper the market growth in the forecast period
- Complex Disease Pathophysiology is Expected to Hinder Market Expansion in the Upcoming Period.
Bronchiectasis Therapeutic Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.3% |
|
Base Year Market Size (2024) |
USD 532.08 million |
|
Forecast Year Market Size (2037) |
USD 1.17 billion |
|
Regional Scope |
|
Bronchiectasis Therapeutic Segmentation
Product Type (Antibiotics, Expectorants)
Based on type, the antibiotic segment in the bronchiectasis therapeutic market is set to hold the highest CAGR of 70% during the forecast period 2025-2037. The growth of this market can be primarily attributed to the back of increasing prevalence of respiratory disorders. As healthcare providers become more aware of the risks of antibiotic overuse, there is a growing demand for targeted antibiotic therapy that is specific to the bacteria causing the infection. Pharmaceutical companies are developing new antibiotics that are specifically designed to treat bacterial infections in patients with bronchiectasis.
Distribution Channel (Hospital, Online, Retail Pharmacies)
In terms of distribution channels, the online pharmacy segment in the bronchiectasis therapeutic market is set to hold the highest CAGR of 50% during the forecast period. Online pharmacies offer patients the convenience of ordering their medication from home and having it delivered directly to their door. This can be especially helpful for patients with bronchiectasis who may have difficulty traveling to a physical pharmacy owing to their symptoms. Online pharmacies can often offer lower prices on medications than traditional brick-and-mortar pharmacies. This is because they have lower overhead costs and can negotiate better deals with drug manufacturers. This segment rapidly grew during the COVID-19 pandemic period as well. CVS Health reported a rise of 1000% in online sales of prescription drugs in covid time.
Our in-depth analysis of the global bronchiectasis therapeutic market includes the following segments:
|
Product Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBronchiectasis Therapeutic Industry - Regional Synopsis
North American Market Forecasts
North America industry is set to account for largest revenue share of 35% by 2037, due to rising substantial cases of bronchiectasis in the region. Due to the increasing prevalence of bronchiectasis, increased R&D activity in the field of drug development, and technological progress in the treatment of bronchiectasis, North America is expected to dominate the global market. In the United States, Bronchiectasis is a disease affecting 350,000 to 500,000 adults. With age, the risk of developing bronchiectasis is increased. Bronchiectasis is more commonly seen in women than men. There are many causes of bronchiectasis, but the cause is not known in about 40% of cases.
APAC Market Statistics
The bronchiectasis therapeutic market in the Asia Pacific is set to grow significantly during the forecast period. As bronchiectasis is a chronic condition that should be treated with lifelong therapy, it is expected to grow more rapidly during the forecast period. The overall cost of the treatment for bronchiectasis is huge, and some healthcare systems are starting to take account of this. In addition, there is an increase in the number of respiratory disorders and a growing aging population. Moreover, Japan is driving the Asia Pacific bronchiectasis therapeutic market revenue growth due to technological advances in the diagnosis and treatment of respiratory disorders as well as a dominant healthcare sector that subsequently raises regional revenues.
Companies Dominating the Bronchiectasis Therapeutic Landscape
- GlaxoSmithKline Plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Reckitt and Benckiser Group Plc
- Zydus Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Insmed Inc.
- Reddy’s Laboratories Ltd
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Boehringer Ingelheim International GmbH
In the News
- GlaxoSmithKline Pharmaceuticals released Trelegy Ellipta to patients with chronic obstructive pulmonary disease in April 2022.
- The first generic version of twice daily PERFOROMIST, a formoterol fumarate inhalation solution, 20 mcg/2 ml, for the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, was officially launched by Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd., in June 2021.
Author Credits: Radhika Pawar
- Report ID: 5679
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
